8-K: N2OFF Stockholders Approve Biotech Merger, Reverse Split

N2OFF, Inc. stockholders approved the acquisition of MitoCareX Bio Ltd., a drug discovery company targeting resistant cancers, alongside a reverse stock split authorization and warrant issuance.

Summary

• Stockholders of N2OFF, Inc. approved the acquisition of MitoCareX Bio Ltd., a biotech company focused on drug discovery for cancer therapeutics.
• The acquisition involves N2OFF purchasing 6,622 shares from SciSparc Ltd for $700,000 and exchanging shares with sellers for 40% of N2OFF's fully diluted capital stock.
• Sellers are entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million over five years, and up to 25% of N2OFF common stock based on milestones.
• N2OFF committed to an initial cash investment of $1,000,000 and financial support for MitoCareX's operations for two years post-closing.
• Stockholders also approved authorizing the Board to effect a reverse stock split within one year, at a ratio between 1-for-2 and 1-for-150.
• The issuance of 1,850,000 common shares upon exercise of a warrant to L.I.A. Pure Capital Ltd. was also approved.
• A 1-for-35 reverse stock split of common stock was effected on September 22, 2025, prior to the meeting.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful stockholder approval of a strategic acquisition into a high-growth biotech sector, which could offer significant future upside. However, the substantial dilution for existing shareholders, the strategic pivot away from core cleantech business, and the inherent risks of drug discovery temper the overall sentiment.

Positives

• Stockholder approval of the MitoCareX acquisition allows N2OFF to diversify into the potentially high-growth cancer therapeutics market.
• MitoCareX focuses on hard-to-treat cancers like pancreatic and non-small cell lung cancer, addressing a significant unmet medical need.
• The global Cancer Therapeutics and Biotherapeutics market is projected to grow from $194.1 billion in 2024 to $344.1 billion by 2031.
• The acquisition includes a commitment from N2OFF to financially support MitoCareX's operations with an initial $1,000,000 cash investment and ongoing support for two years.

Negatives

• The reverse stock split, while approved, can sometimes be perceived negatively by the market as it reduces the number of outstanding shares and increases the per-share price without changing market capitalization, often done to meet listing requirements.
• The company is diversifying from its core cleantech business (solar assets) into biotech, which introduces new operational and market risks.
• The acquisition involves significant share dilution for existing shareholders, with sellers receiving 40% of N2OFF's fully diluted capital stock and potential milestone-based issuances of up to 25%.

Risks

• Successful implementation of potential synergies between N2OFF and MitoCareX is uncertain.
• Operational and business opportunities available to N2OFF following the acquisition of MitoCareX may not materialize as expected.
• The potential benefits MitoCareX can present to N2OFF if and when the transaction closes are subject to various uncertainties.
• The success of N2OFF's collaboration with Solterra Energy Ltd. and entry into future solar projects is not guaranteed.
• The ability to successfully enter the solar PV sector and the profitability of such industry are subject to market conditions and competition.
• The added value of increased capacity in the solar sector is uncertain.
• Market conditions and other risks discussed in N2OFF's Annual Report on Form 10-K filed March 31, 2025, and subsequent SEC filings.

Future Outlook

N2OFF and the sellers are aiming to close the MitoCareX acquisition within the first half of October 2025, subject to the satisfaction of remaining closing conditions. The company anticipates potential synergies and operational opportunities from the acquisition, and is committed to financially supporting MitoCareX's operations for two years post-closing.

Management Comments

• N2OFF's Stockholders Approved a merger with drug discovery company targeting resistant cancers Including pancreatic and non-small cell lung cancer.

Industry Context

N2OFF, traditionally a cleantech company focused on solar energy assets, is making a significant strategic pivot by acquiring MitoCareX Bio Ltd., a biotech company in the cancer therapeutics space. This move positions N2OFF to enter the rapidly growing global Cancer Therapeutics and Biotherapeutics market, estimated at $194.1 billion in 2024 and projected to reach $344.1 billion by 2031. This diversification is a notable shift from its existing solar and post-harvest treatment businesses, aiming to capitalize on the high-growth potential of novel therapies for hard-to-treat cancers.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the acquisition or N2OFF's existing operations against global benchmarks.
• The projected growth of the global Cancer Therapeutics and Biotherapeutics market from $194.1 billion in 2024 to $344.1 billion by 2031 indicates a robust industry, suggesting MitoCareX operates in a high-potential sector.
• MitoCareX's focus on mitochondrial SLC25 protein family and 3D comparative modeling for drug discovery represents a specific approach within the broader cancer therapeutics field, but no direct comparisons to similar projects or companies are provided.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of MitoCareX involves SciSparc Ltd. as one of the sellers.
• Mr. Amitay Weiss serves as Chairman of the Board for both N2OFF and SciSparc Ltd.
• Ms. Liat Sidi serves as a member of the Board of Directors for both N2OFF and SciSparc Ltd.

Stakeholder Impact

• Shareholders will experience significant dilution from the issuance of shares to MitoCareX sellers (40% of fully diluted capital stock, plus potential 25% milestone-based issuances). The reverse stock split (1-for-35 already effected, and authorization for future splits) will reduce the number of shares held but increase the per-share price. The strategic pivot into biotech introduces new risk/reward profiles.
• MitoCareX Employees/Management will become part of a larger, publicly traded entity, with N2OFF appointees reconstituting the board.
• SciSparc Ltd. will receive $700,000 in cash and N2OFF common stock as part of the acquisition, and potentially a share of N2OFF's financing proceeds.

Next Steps

• N2OFF and the sellers aim to close the acquisition of MitoCareX Bio Ltd. within the first half of October 2025, subject to remaining closing conditions.
• Upon closing, MitoCareX's board will be reconstituted with N2OFF appointees.
• N2OFF will financially support MitoCareX's operations for two years following the closing, including an initial cash investment of $1,000,000.
• The Board is authorized to effect a reverse stock split within one year after stockholder approval.

Key Dates

Recommendation

The approval of the MitoCareX acquisition represents a significant strategic shift for N2OFF, moving into the high-growth cancer therapeutics market. While this diversification offers substantial long-term potential, particularly given the market size projections, it also introduces new risks inherent in drug discovery and development. The immediate impact includes significant shareholder dilution and a reverse stock split, which can create short-term volatility and uncertainty. Given the strategic pivot and the time required for biotech development, a 'hold' recommendation is appropriate, allowing investors to observe the integration of MitoCareX and the initial progress of its drug discovery programs before making further investment decisions. The related party transactions also warrant careful monitoring.

Keywords

N2OFF, MitoCareX Bio, Acquisition, Biotech, Cancer Therapeutics, Reverse Stock Split, SEC Filing, NITO, Drug Discovery, Cleantech, Solar Energy, Corporate Governance, Shareholder Meeting, Nasdaq Listing Rules